Clinical Trial Update: Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial of lenalidomide in combination with vaccine therapy for relapsed or refractory multiple myeloma has completed, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2015-07-24